Genprex, Inc. (GNPX-NASDAQ)

Genprex logo1-1

Genprex, Inc.
3300 Bee Cave Road, Suite 650-227
Austin, TX 78746
Phone: (877) 774-GNPX (4679) 

You Might Also Like...

Recent News Releases

Genprex, Inc. (“Genprex” or “the Company”) is a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes. The Company’s oncology program employs its proprietary, non-viral ONCOPREX® Nanoparticle Delivery System, which encapsulates the gene-expressing plasmids using lipid nanoparticles. The resulting product is administered intravenously, where it is taken up by tumor cells that express deficient proteins. Genprex’s lead product candidate, REQORSA™ Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated to treat non-small cell lung cancer (NSCLC) in combination with two leading cancer drugs to potentially improve their benefits—Merck & Company’s Keytruda® (pembrolizumab) and AstraZeneca’s Tagrisso® (osimertinib). The active ingredient in REQORSA is the TUSC2 gene, a tumor suppressor gene, which has inhibitory actions on cancer cell growth. Genprex is also evaluating a gene therapy, GPX-002, for Type 1 and Type 2 diabetes, which is designed to transform alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body’s immune system.

* The Corporate Snapshot was last updated on June 23, 2022.

Latest Research

Genprex Cover Page-1

Unlocking Visibility: Trusted Research by Wall Street Veterans